Clinical efficacy of Dexamethasone Intravitreal Implant (Ozurdex) in patients with retinal vein occlusions

Kulagina A.V.; Gusarevich O.G.; Gusarevich A.A.; Lebedev P.A.; Baltaks A.D.

doi:https://doi.org/

Kulagina A.V.

NUZ "Dorozhnaia klinicheskaia bol'nitsa na stantsii Novosibirsk-Glavnyĭ otkrytogo aktsionernogo obshchestva "Rossiĭskie zheleznye dorogi"

Gusarevich O.G.

GBOU VPO "Novosibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava Rossii

Gusarevich A.A.

NUZ "Dorozhnaia klinicheskaia bol'nitsa na stantsii Novosibirsk-Glavnyĭ otkrytogo aktsionernogo obshchestva "Rossiĭskie zheleznye dorogi"

Lebedev P.A.

NUZ "Dorozhnaia klinicheskaia bol'nitsa na stantsii Novosibirsk-Glavnyĭ otkrytogo aktsionernogo obshchestva "Rossiĭskie zheleznye dorogi"

Baltaks A.D.

NUZ "Dorozhnaia klinicheskaia bol'nitsa na stantsii Novosibirsk-Glavnyĭ otkrytogo aktsionernogo obshchestva "Rossiĭskie zheleznye dorogi"

Clinical efficacy of Dexamethasone Intravitreal Implant (Ozurdex) in patients with retinal vein occlusions

Authors:

Kulagina A.V., Gusarevich O.G., Gusarevich A.A., Lebedev P.A., Baltaks A.D.

More about the authors

Journal: Russian Annals of Ophthalmology. 2014;130(3): 49‑53

Read: 1736 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kulagina AV, Gusarevich OG, Gusarevich AA, Lebedev PA, Baltaks AD. Clinical efficacy of Dexamethasone Intravitreal Implant (Ozurdex) in patients with retinal vein occlusions. Russian Annals of Ophthalmology. 2014;130(3):49‑53. (In Russ.)

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)

Использование инфографики авторами научных работ

Close metadata

Abstract:

Two cases of dexamethasone intravitreal implant (Ozurdex) use are reported. The drug promotes resolution of macular edema and ensures a long-term improvement of visual acuity. The latter may depend on such factors as the duration of the disease and localization of the occlusion. Application of Dexamethasone Intravitreal Implant provides new opportunities for the treatment of retinal vein occlusions.

Keywords:

retinal vein occlusions

macular edema

dexamethasone intravitreal implant

Authors:

Kulagina A.V.

NUZ "Dorozhnaia klinicheskaia bol'nitsa na stantsii Novosibirsk-Glavnyĭ otkrytogo aktsionernogo obshchestva "Rossiĭskie zheleznye dorogi"

Gusarevich O.G.

GBOU VPO "Novosibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava Rossii

Gusarevich A.A.

NUZ "Dorozhnaia klinicheskaia bol'nitsa na stantsii Novosibirsk-Glavnyĭ otkrytogo aktsionernogo obshchestva "Rossiĭskie zheleznye dorogi"

Lebedev P.A.

NUZ "Dorozhnaia klinicheskaia bol'nitsa na stantsii Novosibirsk-Glavnyĭ otkrytogo aktsionernogo obshchestva "Rossiĭskie zheleznye dorogi"

Baltaks A.D.

NUZ "Dorozhnaia klinicheskaia bol'nitsa na stantsii Novosibirsk-Glavnyĭ otkrytogo aktsionernogo obshchestva "Rossiĭskie zheleznye dorogi"

Close metadata

References:

Yau J.W., Lee P., Wong T.Y., Best J., Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern. Med. J. 2008; 38: 904-910.
Mitchell P., Smith W., Chang A. Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study. Arch. Ophthalmol. 1996; 114: 1243-1247.
Green W.R., Chan C.C., Hutchins G.M., Terry J.M. Central retinal vein occlusions: A prospective histopathologic study of 29 eyes in 28 cases. Retina. 1981; 1: 27-55.
Green W.R. Retina. In Spencer WH (Ed): Ophthalmic pathology. An Atlas and Textbook. 3rd Ed. Philadephia. W.B. Saunders. 1985; p. 589.
Frangieh G.T., Green W.R., Barraquer-Somers E., Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch. Ophthalmol. 1982; 100: 1132-1140.
Branch Vein Occlusion Study Group Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch. Ophthalmol. 1986; 104: 34-41.
Rogers S., McIntosh R.L., Cheung N., Lim L., Wang J.J., Mitchell P., Kowalski J.W., Nguyen H., Wong T.Y. International Eye Disease Consortium. The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010; 117: 313-319.
Royal College of Ophthalmologists. Retinal vein occlusion (RVO) interim guidelines. December 2010.
Rehak J., Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr. Eye Res. 2008; 33: 111-131.
Antonetti D.A., Barber A.J., Khin S., Lieth E., Tarbell J.M., Gardner T.W. Penn State Retina Research Group. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes. 1998; 47: 1953-1959.
Noma H., Funatsu H., Mimura T., Harino S., Sone T., Hori S. Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humor of patients with macular edema and central retinal vein occlusion. Acta Ophthalmol. 2010; 88 (6): 646-651.
Campochiaro P.A., Heier J.S., Feiner L., Gray S., Saroj N., Rundle A.C., Murahashi W.Y., Rubio R.G. BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117: 1102-1112.
Brown D.M., Campochiaro P.A., Singh R.P., Li Z., Gray S., Saroj N., Rundle A.C., Rubio R.G., Murahashi W.Y. CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117: 1124-1133.
Antonetti D.A., Wolpert E.B., DeMaio L., Harhaj N.S., Scaduto R.C. Jr. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J. Neurochem. 2002; 80: 667-677.
Nauck M., Karakiulakis G., Perruchoud A.P., Papakonstantinou E., Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur. J. Pharmacol. 1998; 341: 309-315.
Nehme A., Edelman J. Dexamethasone Inhibits High Glucose-, TNF-, and IL-1-Induced Secretion of Inflammatory and Angiogenic Mediators from Retinal Microvascular Pericytes Investigative Ophthalmology & Visual Science. 2008; 49 (5): 2030-2038.
Haller J.A., Bandello F., Belfort R. Jr., Blumenkranz M.S., Gillies M., Heier J., Loewenstein A., Yoon Y.H., Jacques M.L., Jiao J., Li X.Y., Whitcup S.M. OZURDEX GENEVA Study Group. Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. Ophthalmology. 2010; 117: 1134-1146.
Haller J.A., Bandello F., Belfort R. Jr., Blumenkranz M.S., Gillies M., Heier J., Loewenstein A., Yoon Y.H., Jiao J., Li X.Y., Whitcup S.M. Ozurdex GENEVA Study Group, Li J. Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion. Twelve-Month Study Results. Ophthalmology. 2011; 118: 2453-2460.
Augustin A.J., Sahel J.A., Cerulli L., Texier-Richard B., Buchholz P.M., Kobelt G. Treating retinal vein occlusions in France, Germany, and Italy: an analysis of treatment patterns, resource consumption, and costs. Eur. J. Ophthalmol. 2012; 22 (5): 776-784.
Coscas G., Loewenstein A., Augustin A., Bandello F., Battaglia Parodi M., Lanzetta P., Monés J., de Smet M., Soubrane G., Staurenghi G. Management of Retinal Vein Occlusion - Consensus Document. Ophthalmologica. 2011; 226: 4-28.
Kuppermann B.D., Blumenkranz M.S., Haller J.A., Williams G.A., Weinberg D.V., Chou C., Whitcup S.M. Dexamethasone DDS Phase II Study Group. Randomized Controlled Study of an Intravitreous Dexamethasone Drug Delivery System in Patients With Persistent Macular Edema. Arch. Ophthalmol. 2007; 125: 309-317.